Category: 36958-61-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

lodomethylcyclopropane (0.03 mL, 0.20 mmol) was added to a stirring mixture of N-(1 -cyanocyclopropyl)-N-[[3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo- 1H- quinazolin-6-yl]sulfonyl]acetamide (76 mg, 0.170 mmol) and potassium carbonate (92 mg, 0.66 mmol) in DMF (3 mL) and left to stir at room temperature for 16 h. Concentrated ammonia (100 muL) was added and the mixture heated to 40 C for 10 min. The mixture was allowed to cool and DCM (8 mL) and saturated aqueous ammonium chloride solution (8 mL) was added and the mixture stirred for 5 min. The DCM layer was isolated by passing through a hydrophobic frit and the aqueous layer washed with DCM (10 mL). The combined DCM extracts were concentrated under reduced pressure and purified by prep HPLC (low pH) yielding the desired product (8 mg, 0.017 mmol, 10%) as a white powder.This compound was prepared from 5-(bromomethyl)-3-methyl-1 ,2-oxazole (0.02 mL, 0.20 mmol) and N-(1 -cyanocyclopropyl)-N-[[3-[(2-methylthiazol-5-yl)methyl]-2,4- dioxo- 7H-quinazolin-6-yl]sulfonyl]acetamide (76 mg, 0.170 mmol) according to the method described in Example 399. This gave the desired product (10 mg, 0.020 mmol, 12%) as a white powder

36958-61-9, 36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; MCGONAGLE, Alison E.; JORDAN, Allan; WASZKOWYCZ, Bohdan; HUTTON, Colin; WADDELL, Ian; HITCHIN, James R.; SMITH, Kate Mary; HAMILTON, Niall M.; (497 pag.)WO2016/92326; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

General procedure: Amine (0.25 mmol), and bromide (0.25 mmol) were taken up in acetonitrile (0.3 mL) in a conical vial equipped with a stirrer bar. Potassium carbonate (0.5 mmol) was added followed by potassium iodide (10 mol%) if required. The vial was sealed with a screwcap and the reaction was stirred at 40 C until thin layer chromatography (TLC) indicated complete consumption of the starting materials. A precipitate was formed during the reaction which was removed by filtration and the filtrate concentrated under reduced pressure. The residue was purified by flash column chromatography and sent to the Netherlands Cancer Institute (NKI) for biological testing.

36958-61-9, 36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Article; Milne, Kirsty; Sun, Jianhui; Zaal, Esther A.; Mowat, Jenna; Celie, Patrick H.N.; Fish, Alexander; Berkers, Celia R.; Forlani, Giuseppe; Loayza-Puch, Fabricio; Jamieson, Craig; Agami, Reuven; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2626 – 2631;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

General procedure: Amine (0.25 mmol), and bromide (0.25 mmol) were taken up in acetonitrile (0.3 mL) in a conical vial equipped with a stirrer bar. Potassium carbonate (0.5 mmol) was added followed by potassium iodide (10 mol%) if required. The vial was sealed with a screwcap and the reaction was stirred at 40 C until thin layer chromatography (TLC) indicated complete consumption of the starting materials. A precipitate was formed during the reaction which was removed by filtration and the filtrate concentrated under reduced pressure. The residue was purified by flash column chromatography and sent to the Netherlands Cancer Institute (NKI) for biological testing.

36958-61-9, 36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Article; Milne, Kirsty; Sun, Jianhui; Zaal, Esther A.; Mowat, Jenna; Celie, Patrick H.N.; Fish, Alexander; Berkers, Celia R.; Forlani, Giuseppe; Loayza-Puch, Fabricio; Jamieson, Craig; Agami, Reuven; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2626 – 2631;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A stirred suspension of12(1 g, 3.9 mmol), 5-(bromomethyl)-3-methyl-1,2-oxazole (0.48 mL, 4.3 mmol) and potassium carbonate (1.13 g, 8.2 mmol) in DMF (10 mL) was heated to 80 C for 4 h. After cooling to room temperature the reaction mixture was added to ice-water (100 mL) and stirred for 30 min. The resulting pink precipitate was collected by filtration to afford the title compound (0.89 g, 65%) as a pink powder. 1H NMR (300 MHz, DMSO-d6) delta 8.05-8.00 (m, 2H), 7.94-7.88 (m, 2H), 6.65 (s, 1H), 6.60 (s, 1H), 5.54 (s, 2H), 4.32 (q,J= 7.1 Hz, 2H), 2.25 (s, 3H), 1.31 (t,J= 7.1 Hz, 3H). LC-MS: (High pH) tR1.11 min,m/z351.2 [M-H]-, 96% purity, 36958-61-9

As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Article; Mould, Daniel P.; Bremberg, Ulf; Jordan, Allan M.; Geitmann, Matthis; Maiques-Diaz, Alba; McGonagle, Alison E.; Small, Helen F.; Somervaille, Tim C.P.; Ogilvie, Donald; Bioorganic and Medicinal Chemistry Letters; vol. 27; 14; (2017); p. 3190 – 3195;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

Sodium hydride (60% w/w) (34.1 mg, 0.85 mmol) was added to a stirring solution of 7-benzylsulfanyl-4-(cyclopropanecarbonyl)-2H-isoquinolin-1 -one (220. mg, 0.66 mmol) in DMF (8 mL). After 15 min 5-(bromomethyl)-3-methyl-1 ,2-oxazole (0.15 mL, 0.85 mmol) was added and the reaction mixture stirred at ambient temperature for 1 h. DCM (25 mL) and saturated aq. NaHC03 (25 mL) were added and the mixture stirred for 5 min. The DCM layer was isolated by passing through a hydrophobic frit and the aqueous layer washed with DCM. The combined DCM extracts were concentrated under reduced pressure and purified by automated column chromatography, SiO2, eluent 0-100% EtOAc in iso- Hexane to yield 7-benzylsulfanyl-4-(cyclopropanecarbonyl)-2-[(3-methylisoxazol-5- yl)methyl]isoquinolin-1 -one (263 mg, 0.61 mmol, 93%). Used directly in the synthesis of Intermediate S10-C1, 36958-61-9

As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; MCGONAGLE, Alison E.; JORDAN, Allan; WASZKOWYCZ, Bohdan; HUTTON, Colin; WADDELL, Ian; HITCHIN, James R.; SMITH, Kate Mary; HAMILTON, Niall M.; (497 pag.)WO2016/92326; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Potassium hydroxide (1.588 g) was added to a solution of 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine (2 g), 5-(bromomethyl)-3-methylisoxazole (1.8 g) and TBAI (3.48 g) in THF at 60C. The mixture was stirred under a nitrogen atmosphere at 60C for 2 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The organic layer was sequentially washed with water and a saturated brine, then dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane/ethyl acetate) to obtain the title compound (0.89 g). 1H NMR (300 MHz, DMSO-d6) delta 2.18 (3H, s), 2.63 (3H, s), 5.71 (2H, s), 6.38 (1H, s), 8.40-8.42 (1H, m), 8.42-8.46 (1H, m)., 36958-61-9

36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; KAWAKITA Youichi; KOJIMA Takuto; NII Noriyuki; ITO Yoshiteru; SAKAUCHI Nobuki; BANNO Hiroshi; LIU Xin; ONO Koji; IMAMURA Keisuke; IMAMURA Shinichi; (165 pag.)EP3450436; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation 67: 6-(5-chloro-2-{[(2,4-dimethoxyphenyl)methyl](oxan-4-yl)amino}pyrimidin- 4-yl)-2-[(3-methy 1-1 ,2-oxazol-5-yl)methyl]-2,3-dihydro-1 H-isoindol-1 -one (1591) (1592) A stirred suspension of 6-(5-chloro-2-{[(2,4-dimethoxyphenyl)methyl](oxan-4-yl)arnino}pyrimidin- 4-yl)-2,3-dihydro-1 H-isoindol-1-one (100 mg, 0.20 mmol) in THF (2 mL) was cooled to -78 C and treated with a lithium bis(trimethylsilyl)amide (1 M in THF, 0.3 mL, 0.3 mmol). The resulting suspension was stirred for 15 min before 5-(bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) was added. The resulting suspension was allowed to reach RT and the resulting orange solution was stirred for 18 h. The mixture was treated at room temperature with more 5- (bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) and stirred for 5 h. Lithium (1593) bis(trimethylsilyl)amide (1 M in THF, 0.15 mL, 0.15 mmol) was added and the mixture was stirred for 15 min before 5-(bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) was added and the mixture stirred for 3 days. Brine (5 mL) was added and the mixture was extracted with ethyl acetate (3×5 mL). The combined organic phases were washed with brine (5 mL), dried (Na2S04) and concentrated. Purification by chromatography (S1O2, 10-100% ethyl acetate in iso-hexane) gave the title compound (79 mg, 67%) as a yellow foam. LC-MS: [M+H]+ =590., 36958-61-9

36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; OTSUKA PHARMACEUTICAL CO., LTD.; BERDINI, Valerio; BUCK, Ildiko Maria; DAY, James Edward Harvey; GRIFFITHS-JONES, Charlotte Mary; HEIGHTMAN, Thomas Daniel; HOWARD, Steven; MURRAY, Christopher William; NORTON, David; O’REILLY, Marc; WOOLFORD, Alison Jo-Anne; COOKE, Michael Liam; COUSIN, David; ONIONS, Stuart Thomas; SHANNON, Jonathan Martin; WATTS, John Paul; (867 pag.)WO2017/68412; (2017); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

-Benzylsulfanyl-4-chloro-2H-phthalazin-1 -one (500. mg, 1 .65 mmol) in DMF (15 mL) was cooled in an ice bath, treated with sodium hydride (60% w/w) (69.35 mg, 1 .73 mmol), and the resulting mixture was stirred at ambient temperature for 1 h. 5- (Bromometh

36958-61-9, As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; MCGONAGLE, Alison E.; JORDAN, Allan; WASZKOWYCZ, Bohdan; HUTTON, Colin; WADDELL, Ian; HITCHIN, James R.; SMITH, Kate Mary; HAMILTON, Niall M.; (497 pag.)WO2016/92326; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

STEP A: ethyl 4-bromo-5-methyl-l-((3-methylisoxazol-5-yl)methyl)-lH-pyrazole- 3-carboxylate and ethyl 4-bromo-3-methyl-l-((3-methylisoxazol-5-yl)methyl)-lH-pyrazole- 5-carboxylate and [1124] To a mixture of ethyl 4-bromo-3-methyl-lH-pyrazole-5-carboxylate (0.331 g, 1.420 mmol) in DMF (10 mL) were added CS2CO3 (1.157 g, 3.55 mmol) and 5-(bromomethyl)-3- methylisoxazole (0.5 g, 2.84 mmol). The reaction mixture was stirred at room temperature for 20 hours and then diluted with water. The product was extracted into EtOAc. The organic phase was dried over Na2S04 and concentrated to give the title compounds as a crude mixture that was used without further purification (0.24 g).

36958-61-9, The synthetic route of 36958-61-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; CHERUVALLATH, Zacharia; ERICKSON, Philip; FENG, Jun; KOMANDLA, Mallareddy; LAWSON, John David; MCBRIDE, Christopher; MIURA, Joanne; MURPHY, Sean; TANG, Mingnam; TON-NU, Huong-Thu; WO2013/130855; (2013); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

Example 13 (5RS)-2-[(3-Methyl-1,2-oxazol-5-yl)methyl]-5-(pyrrolidin-1-ylcarbonyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (Racemate) (5RS)-5-(Pyrrolidin-1-ylcarbonyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (racemate) (40.0 mg, 169 mumol) was initially charged in acetonitrile (2.0 ml). Caesium carbonate (82.7 mg, 254 mumol) and 5-(bromomethyl)-3-methyl-1,2-oxazole (32.8 mg, 186 mumol) were subsequently added. After stirring at room temperature for 2 days, the reaction mixture was admixed with water and ethyl acetate. The organic phase was removed and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed with saturated aqueous sodium chloride solution, dried over sodium sulphate and filtered, and the filtrate was concentrated. 18.6 mg (33% of theory) of the title compound were obtained. LC-MS (Method 3): Rt=0.89 min; MS (ESIpos): m/z=332 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) delta [ppm]: -0.008 (0.87), 0.008 (0.76), 1.686 (0.49), 1.709 (0.99), 1.720 (1.17), 1.732 (0.87), 1.753 (0.57), 1.772 (1.53), 1.789 (2.62), 1.806 (2.01), 1.822 (0.60), 1.892 (0.62), 1.909 (1.85), 1.925 (2.33), 1.942 (1.50), 1.959 (0.66), 1.972 (0.52), 1.983 (0.78), 1.995 (0.71), 2.004 (0.63), 2.014 (0.50), 2.019 (0.48), 2.030 (0.68), 2.039 (0.56), 2.046 (0.46), 2.055 (0.49), 2.201 (16.00), 2.215 (0.69), 2.417 (0.49), 2.523 (1.09), 2.565 (0.86), 2.580 (0.74), 2.590 (0.68), 2.602 (1.21), 2.615 (0.66), 2.643 (0.48), 3.242 (0.75), 3.254 (0.74), 3.271 (1.33), 3.288 (0.70), 3.322 (0.97), 3.339 (1.33), 3.351 (0.50), 3.357 (0.70), 3.369 (0.78), 3.454 (0.86), 3.462 (0.63), 3.471 (0.53), 3.479 (1.08), 3.496 (0.47), 3.589 (0.50), 3.606 (1.03), 3.614 (0.52), 3.623 (0.59), 3.631 (0.79), 3.703 (0.42), 4.495 (0.41), 4.510 (0.41), 4.723 (0.92), 4.732 (1.05), 4.738 (1.20), 4.747 (0.90), 4.940 (4.70), 4.982 (0.54), 6.223 (3.16).

36958-61-9, As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; BIBER, Nicole; BROCKSCHNIEDER, Damian; GERICKE, Kersten Matthias; KOeLLING, Florian; LUSTIG, Klemens; MEDING, Joerg; MEIER, Heinrich; NEUBAUER, Thomas; SCHAeFER, Martina; TIMMERMANN, Andreas; ZUBOV, Dmitry; TERJUNG, Carsten; LINDNER, Niels; BADOCK, Volker; MOOSMAYER, Dieter; MIYATAKE ONDOZABAL, Hideki; MOORE, Steven; SCHULZ, Alexander; (458 pag.)US2019/160048; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem